Drug Trial Radar · NCT01976104
Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
Last checked: Nov 20, 2026Latest source record: Feb 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
204
Actual
Start
Nov 2013
Primary completion
Jan 30, 2017
Study completion Feb 21, 2017
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Nov 5, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel group study using avatrombopag to treat adults with thrombocytopenia associated with liver disease. The study will evaluate avatrombopag in the treatment of thrombocytopenia associated with liver disease prior to an elective procedure to reduce the need for platelet transfusions or any rescue procedure for bleeding due to procedural and post-procedural bleeding complications. Participants will be enrolled into 2 cohorts according to mean baseline platelet count and, within each baseline platelet count cohort will be further stratified by risk of bleeding associated with the elective procedure (low, moderate, or high) and hepatocellular carcinoma (HCC) status (Yes or No).
Conditions
- Thrombocytopenia Associated With Liver Disease
Interventions
avatrombopag (lower baseline platelet count)Drug
60 mg avatrombopag (3 x 20 mg tablets)
placebo (lower baseline platelet count)Drug
60 mg placebo (3 x 20 mg matching placebo tablets)
avatrombopag (higher baseline platelet count)Drug
40 mg avatrombopag (2 x 20 mg tablets)
placebo (higher baseline platelet count)Drug
40 mg placebo (2 x 20 mg matching placebo tablets)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Did Not Require a Platelet Transfusion After Randomization and up to 7 Days Following a Scheduled ProcedureTime frame: Randomization (Visit 2), up to 7 Days following a scheduled procedure
Locations
120 sites in 17 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Phoenix, Arizona
Site not named
Little Rock, Arkansas
Site not named
Coronado, California
Site not named
Loma Linda, California
Site not named
Denver, Colorado
Site not named
Miami, Florida
Site not named
Maywood, Illinois
Site not named
Indianapolis, Indiana
Site not named
Kansas City, Kansas
Site not named
New Orleans, Louisiana
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Detroit, Michigan
Site not named
Kansas City, Missouri
Site not named
New York, New York
Site not named
Statesville, North Carolina
Site not named
Charleston, South Carolina
Site not named
Houston, Texas
Site not named
San Antonio, Texas
Site not named
Charlottesville, Virginia
Site not named
Richmond, Virginia
Site not named
Seattle, Washington
Site not named
Ciudad Autonoma Buenos Aires, Argentina
Site not named
Córdoba, Argentina
Site not named
Rosario, Argentina
Site not named
Clayton, Victoria, Australia
Site not named
Footscray, Victoria, Australia
Site not named
Melbourne, Victoria, Australia
Site not named
Parkville, Victoria, Australia
Site not named
Edegem, Belgium
Site not named
Ghent, Belgium
Site not named
Liège, Belgium
Site not named
Aracaju, Brazil
Site not named
Botucatu, Brazil
Site not named
Porto Alegre, Brazil
Site not named
Salvador, Brazil
Site not named
Calgary, Canada
Site not named
Edmonton, Canada
Site not named
Hefei, Anhui, China
Showing 40 of 120 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.